Abstract
The patients of a multiple sclerosis (MS) incidence cohort with 25 years of longitudinal follow-up were typed for HLA-DR and DQ. This type of cohort provides reliable data for gene frequencies and prognostic studies. The influence of sampling bias, mainly due to mortality during the long follow-up, was accounted for. A positive association between MS and DR15,DQ6 was confirmed, but this haplotype did not influence prognosis. There was no difference in haplotype frequency between relapsing-remitting and primary chronic progressive MS. DR17,DQ2 was significantly over-represented in the quartile with the most malignant course. The haplotype DR1,DQ5, which was found rather less frequently in MS patients, also tended to be associated with a poorer prognosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Batchelor JR, Morris PJ (1978) Joint report (HLA and disease). In: Bodmer WF, Batchelor JR, Bodmer JG, Festenstein H, Morris PJ (eds) Histocompatibility testing 1977. Munksgaard, Copenhagen, pp 207–210
Bidwell JL, Bignon JD (1991) DNARFLP methods and interpretation scheme for HLA-DR and DQ typing. Eur J Immunogenet 18:5–22
Bidwell JL, Bidwell EA, Savage DA, Middleton D, Klouda PT, Bradley BA (1988) A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10. Transplantation 45:640–646
Bidwell JL, Bidwell EA, Bradley BA (1990) HLA class II genes: typing by DNA analysis. Baillière's Clin Haematol 3:355–384
Carlsson B, Wallin J, Böhme J, Möller E (1987) HLA-DR-DQ haplotypes defined by restriction fragment analysis. Correlation to serology. Hum Immunol 20:95–113
Dejaegher L, Bruyere M de, Ketelaer P, Carton H (1983) HLA antigens and progression of multiple sclerosis. II. J Neurol 229:167–174
Duquette P, Décary F, Pleines J, Boivin D, Lamoureux G, Cosgrove JBR, Lapierre Y (1985) Clinical subgroups of multiple sclerosis in relation to HLA: DR allelles as possible markers of disease progression. Can J Neurol Sci 12:106–110
Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W, Murray TJ, Seland P, Duquette P, Grey T, Nelson R, Nicolle M, Brunet D (1986) A population-based study of multiple sclerosis in twins. N Engl J Med 315: 1638–1642
Engell T, Raun NE, Thomsen M, Platz P (1982) HLA and heterogeneity of multiple sclerosis. Neurology 32: 1043–1046
Francis DA, Batchelor JR, McDonald WI, Hing SN, Dodi IA, Fielder AHI, Hern JEC, Downie AW (1987) Multiple sclerosis in Scotland. An association with HLA-DQw1. Brain 110: 181–196
Francis DA, Thompson AJ, Brookes P, Davey N, Lechler RI, McDonald WI, Batchelor JR (1991) Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ? Hum Immunol 32:119–124
Gorodezky C, Najera R, Rangel BE, Castro LE, Flores J, Velazquez J, Granados J, Sotelo J (1986) Immunogenetic profile of multiple sclerosis in Mexicans. Hum Immunol 16:364–374
Haegert DG, Michaud M, Schwab C, Tansey C, Décary F, Francis G (1989) HLA-DRß, -DQa, and -DQß restriction fragment length polymorphism in multiple sclerosis. J Neurosci Res 23:46–54
Ilonen J, Lagerstedt A, Koskimies S, Reunanen M (1983) HLA-Dwl and BfF as protective markers in multiple sclerosis. J Neuroimmunol 5:283–288
Jersild C, Hansen GS, Svejgaard A, Fog T, Thomsen M, Dupont B (1973) Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet II:1221–1225
Kurdi A, Ayesh I, Abdallat A, Maayta U, McDonald WI, Compston DAS, Batchelor JR (1977) Different B lymphocyte alloantigens associated with multiple sclerosis in Arabs and north Europeans. Lancet I:1123–1125
Kurtzke JF (1961) On the evaluation of disability in multiple sclerosis. Neurology 11:686–694
Larhammar D, Schenning L, Gustafsson K, Wiman K, Claesson L, Rask L, Peterson PA (1982) Complete amino acid sequence of an HLA-DR antigen-like β-chain as predicted from the nucleotide sequence: similarities with immunoglobulins and HLA-A, -B, and -C antigens. Proc Natl Acad Sci USA 79:3687–3691
Larsen JP, Kvaale G, Riise T, Nyland H, Aarli JA (1985) Multiple sclerosis — more than one disease? Acta Neurol Scand 72:145–150
Madigand M, Oger JJ-F, Fauchet R, Sabouraud O, Genetet B (1982) HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci 53:519–529
Marrosu MG, Muntovi F, Murru MR, Spinicci G, Pischedda MP, Goddi F, Cossu P, Pirastu M (1988) Sardinian multiple sclerosis is associated with HLA-DR4: a serologic and molecular study. Neurology 38:1749–1753
Naito S, Kuroiwa Y, Itoyama T, Tsubaki T, Horikawa A, Sasazuki T, Noguchi S, Ohtsuki S, Tokuomi H, Miyatake T, Takahata N, Kawanami S, McMichael AJ (1978) HLA and Japanese MS. Tissue Antigens 12:19–24
Olerup O, Hillert J (1991) HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 38:1–15
Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Möller E, Carlsson B, Wallin J (1989) Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogentically distinct disease entities. Proc Natl Acad Sci USA 86: 7113–7117
Paty DW, Dossetor JB, Stiller CR, Cousin HK, Marchuk L, Furesz J, Boucher DW (1977) HLA in multiple sclerosis. J Neurol Sci 32:371–379
Payami H, Joe S, Farid NR, Stenszky V, Chan HS, Yeo PPB, Cheah JS, Thomson G (1989) Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves' disease. Am J Hum Genet 45: 541–546
Poser C, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis. Ann Neurol 13:227–231
Poser S, Ritter G, Grosse-Wilde H, Kuwert EK, Raun NE (1981) HLA-antigens and the prognosis of multiple sclerosis. J Neurol 225:219–221
Poser S, Bauer HJ, Poser W (1982) Prognosis of multiple sclerosis. Results from an epidemiological area in Germany. Acta Neurol Scand 65:347–354
Reekers P, Hommes OR, Creemers-Molenaar J, Wijnings J, Kunst VAJM, Rood JJ van (1977) HLA-typing and lymphocyte population studies in patients with multiple sclerosis. J Neurol Sci 33:143–153
Runmarker B, Andersen O (1993) Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow-up. Brain 116:117–134
Skegg DCG (1991) Multiple sclerosis: nature or nurture? BMJ 302:247–248
Southern EM (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98:503–517
Stendahl-Brodin L, Link H, Möller E, Norrby E (1979) Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG ind CSF. Acta Neurol Scand 59:297–308
Svenningsson A, Runmarker B, Lycke J, Andersen O (1990) Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. Acta Neurol Scand 82:161–168
Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DPE, McDonald WI (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53–62
Tonnelle C, DeMars R, Long EO (1985) DOß: a new β chain gene in HLA-D with a distinct regulation of expression. EMBO J 4:2839–2847
Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Gen 19:251–253
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Runmarker, B., Martinsson, T., Wahlström, J. et al. HLA and prognosis in multiple sclerosis. J Neurol 241, 385–390 (1994). https://doi.org/10.1007/BF02033356
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02033356